Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER - Free Report) in a research note published on Thursday,Benzinga reports.
Other equities analysts have also issued research reports about the company. StockNews.com lowered Omeros from a "hold" rating to a "sell" rating in a research report on Tuesday. Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday. They issued a "buy" rating and a $9.00 price target for the company.
Get Our Latest Analysis on Omeros
Omeros Stock Up 65.9 %
Shares of NASDAQ:OMER traded up $2.76 during trading on Thursday, hitting $6.95. The stock had a trading volume of 14,179,323 shares, compared to its average volume of 459,267. The company has a market capitalization of $402.75 million, a PE ratio of -2.23 and a beta of 1.47. The firm's fifty day moving average is $4.02 and its 200 day moving average is $4.05. Omeros has a 12 month low of $1.38 and a 12 month high of $7.51.
Hedge Funds Weigh In On Omeros
Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. SPC Financial Inc. purchased a new stake in shares of Omeros during the third quarter valued at $77,000. SG Americas Securities LLC bought a new stake in Omeros in the 3rd quarter worth about $80,000. Oppenheimer & Co. Inc. purchased a new position in Omeros in the 1st quarter worth about $85,000. Finally, Comerica Bank lifted its stake in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company's stock valued at $104,000 after acquiring an additional 5,000 shares during the period. 48.79% of the stock is currently owned by institutional investors.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
See Also
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.